Search
Factor XIII (human)
go.drugbank.com/drugs/DB12909ApprovedInvestigationalWhen activated by thrombin at the site of injury, the FXIII pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit. … Factor XIII (Human), available as the commercially available product Corifact, is approved by the Food and Drug Administration for routine prophylactic treatment and peri-operative management of surgical
Rotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalIt was approved by the European Medicines Agency in 2006 and by the FDA in 2007. … Rotigotine was developed by Aderis Pharmaceuticals. In 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany.
Meprobamate
go.drugbank.com/drugs/DB00371ApprovedIllicitIt is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. … Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated).
Fibrinogen human
go.drugbank.com/drugs/DB09222ApprovedInvestigationalIt works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting.
Pegvaliase
go.drugbank.com/drugs/DB12839ApprovedInvestigationalPhenylketonuria is a rare autosomal recessive disorder that is characterized by deficiency of the enzyme phenylalanine hydroxylase (PAH) [A33284] and affects about 1 in 10,000 to 15,000 people in the United … The primary goal of lifelong treatment of PKU, as recommended by the American College of Medical Genetics and Genomics (ACMG) guidelines, is to maintain blood Phe concentration in the range of 120 µmol
Felbamate
go.drugbank.com/drugs/DB00949ApprovedFelbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization). Alternatively, it is used to treat par...
Desflurane
go.drugbank.com/drugs/DB01189ApprovedInvestigationalDesflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as methoxyflurane, sevoflurane, enflurane, or isoflurane. . It was developed in the late 1980s out of ...
Human vaccinia virus immune globulin
go.drugbank.com/drugs/DB14112ApprovedInvestigationalThe IgG fraction is purified by the anion-exchange column chromatography method and the solution is solvent/detergent-treated to sterilize the compound [A33814]. … Nevertheless, VIG by virtue of the way it is produced is a poorly characterized and highly variable human product that is only available in very limited quantities - all factors that may intervene with
Moxetumomab pasudotox
go.drugbank.com/drugs/DB12688ApprovedInvestigational[A38864] It was developed by Astra Zeneca and FDA approved on September 13, 2018, after being granted the status of Fast Track, Priority Review and Orphan Drug designations.[L4568] … [A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW.
Ibalizumab
go.drugbank.com/drugs/DB12698ApprovedInvestigationalIn October 2022, the FDA approved the administration of Trogarzo (ibalizumab-uiyk) by intravenous push, allowing for a faster drug administration.[L43443,L43448] … It has been developed by Taimed biologics and Theratechnologies [L1558, L1554]. This drug was approved in March 2018 for the management of treatment-resistant HIV [L1554].